Bond.az White LogoBond.az Black Logo

Jefferies downgrades ZoomInfo stock on AI

Jefferies downgrades ZoomInfo to Hold, cuts price target to $4.00 on weak demand and AI adoption headwinds.

Harper Clark
ByHarper Clark- Senior Editor
|
0

Bond.az - Jefferies downgraded ZoomInfo Technologies (NASDAQ:ZI) to Hold from Buy on Thursday and cut its price target to $4.00 from $12.00, citing weak client demand and changing customer behavior driven by artificial intelligence adoption.

The stock currently trades at $3.67, hovering near its 52-week low of $3.65, with shares down 61% over the past year.

Analyst Surinder Thind said the firm has materially reduced its outlook for revenue growth in 2026 and does not expect conditions to improve in 2027. Client demand has been weak for two years, and AI has begun to penetrate enterprise workflows in ways that negatively impact purchasing decisions.

Clients have started to prefer building their own workflows and analytics around ZoomInfo's data rather than subscribing to the company's software. Management has begun transitioning clients from a subscription-based model to a usage-based model.

The transition is expected to take 12 to 18 months and lead to revenue declines in the near term. Jefferies said it prefers to move to the sidelines until it has better visibility on the transition and its likelihood of succeeding.

The firm said it does not foresee a catalyst that would take the shares materially higher from current levels despite the stock's correction.

More News
2026-06-01 12:02
|
743

Legend Biotech Buy Rating Reiterated

H.C. Wainwright reiterated its Buy rating for Legend Biotech with a $50 target. Revenue up 56% over twelve months.

0
2026-06-01 12:01
|
475

Cogent Stock Price Target Raised to $55

Cogent Biosciences PEAK trial: combination therapy shows 45.6% response rate, 16.5 months PFS, FDA accepts NDA. H.C. Wainwright raises price target to $55.

0
2026-06-01 12:00
|
842

H.C. Wainwright Reaffirms Mineralys Buy

H.C. Wainwright reiterated a Buy rating on Mineralys Therapeutics with a $56 price target after positive trial data.

0
2026-06-01 10:33
|
714

Goldman Sachs Upgrades Marriott Vacations Stock

Goldman Sachs upgrades Marriott Vacations stock to Buy, price target $100. Execution potential drives earnings upside.

0
2026-06-01 10:32
|
730

Goldman Sachs Upgrades Travel + Leisure Stock to Buy

Goldman Sachs upgraded Travel + Leisure stock to Buy with a $85 price target. Learn about the company's financials, dividends, and market outlook.

0
2026-06-01 10:32
|
238

Canaccord Initiates Rare Earths Americas with Buy

Canaccord Genuity initiates Rare Earths Americas with a buy rating and $25 target. Stock at $21.85, offering 14% upside potential.

0
2026-06-01 10:30
|
651

BofA Raises Icon Stock Target to $125 on Bookings

BofA Securities raised Icon plc price target to $125, maintains Underperform. Improved booking trends and Q4 results drive revision.

0
2026-06-01 10:03
|
748

RBC Capital: Sprouts faces Kroger risk

RBC Capital keeps Sprouts rating but sees risks from Kroger price cuts. Analysis and outlook on Bond.az.

0
2026-06-01 09:02
|
551

CLSA Rates Chagee Hold on Margins

CLSA initiated Chagee Holdings with Hold rating and $10 target. Bond.az analysis reveals stock may be undervalued. Read more.

0
2026-06-01 08:31
|
594

Barclays Downgrades Sensata Stock on Valuation

Barclays downgrades Sensata stock to Equalweight on valuation concerns, but raises price target to $53. Stock surged 92% in past year.

0
2026-06-01 08:05
|
946

UBS Initiates Veritone Coverage with Neutral

UBS initiated coverage on Veritone with a Neutral rating and $2.50 price target. The AI company is better positioned for growth after transformation.

0
2026-06-01 08:02
|
892

JMP Securities Initiates Microsoft with Outperform on AI Strategy

JMP Securities initiates Microsoft with Market Outperform rating and $550 target on AI strategy. Revenue growth expected to reach 17% in FY2026.

0
...